Roivant discontinues blood cancer program as it fails to revive old Eisai drug, to dissolve Hemavant
Roivant disclosed Tuesday morning that it has stopped work on a treatment for myelodysplastic syndromes, a precursor disease to acute myeloid leukemia, after an interim analysis of a Phase I/II study. The company also confirmed to Endpoints News that it plans to dissolve one if its ‘vants,’ Hemavant.
The asset, named RVT-2001, was the sole program housed by Hemavant, a Roivant subsidiary which launched in 2022 in an effort to revive the candidate.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
